Search Within

Isabelle C Riviere

  1. "Jae Park"
  2. "Meeting abstract"
  3. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Meeting Abstract (55)
Groups
  1. Adult Leukemia (55)
  2. Center for Hematologic Malignancies (55)
  3. Department of Medicine (55)
  4. GSK Faculty (55)
  5. Hematologic Malignancies Research (55)
  6. Hematologic Malignancies, Division of (55)

More Groups

People
  1. Jae Park (55)
  2. Michel Sadelain (55)
  3. Renier Brentjens (49)
  4. Xiuyan Wang (41)
  5. Kevin Curran (20)
  6. Brigitte Senechal (19)

More People

Years
  1. 2023 (3)
  2. 2022 (4)
  3. 2021 (4)
  4. 2020 (1)
  5. 2019 (3)
  6. 2018 (2)

More Years

Publications
  1. Blood (21)
  2. Journal of Clinical Oncology (11)
  3. Haematologica (5)
  4. Molecular Therapy (5)
  5. Cancer Research (3)
  6. Hematological Oncology (3)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. American Society of Clinical Oncology (11)
  3. Nature Publishing Group (7)
  4. Ferrata Storti Foundation (5)
  5. American Association for Cancer Research (3)
  6. Wiley Blackwell (3)

More Publishers

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chimeric antigen receptor T cells for cancer immunotherapy
    Meeting Abstract

    Curran, K. J.; Silverman, L. B.; Kobos, R.; Kernan, N. A.; Margossian, S. P.; Park, J. H.; Sauter, C. S.; Szenes, V.; Wang, X. Y.; O'Reilly, R. J.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL
    Meeting Abstract

    Curran, K. J.; Riviere, I.; Silverman, L. B.; Kobos, R.; Shukla, N.; Steinherz, P. G.; Boulad, F.; Prockop, S.; Scaradavou, A.; Margossian, S. P.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Phase I clinical trial of autologous CD19-targeted 19-28z CAR T cells in adult patients with Relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Halton, E.; Quintanilla, H.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R. J.
    Molecular Therapy (2015)

    Fulltext@MSK | Save
  • Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y.; Wang, X. Y.; Purdon, T.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bartido, S.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    Meeting Abstract

    Sadelain, M.; Brentjens, R.; Davila, M.; Riviere, I.; Wang, X. Y.; Bartido, S.; Park, J.; Bouhassira, D.; Curran, K.; Chung, S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y. J.; Wang, X. Y.; Purdon, T. J.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Blood (2014)

    Fulltext@MSK | Save